BLRX - BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer | Benzinga
BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
The pilot phase of the Phase 2 study enrolled 11 patients with metastatic pancreatic cancer.
As of May 2023, 6 patients (55%) experienced a partial response (PR), of which 4 (36%) were confirmed PRs, ...